摘要
目的研究T细胞非霍奇金淋巴瘤(T—NHL)患者血清差异蛋白质质谱的表达及其临床价值。方法应用蛋白芯片表面加强激光解吸电离一飞行时间质谱(SELDI-TOF—MS)技术wcx-2芯片检测36例T—NHL患者和30例弥漫大B细胞淋巴瘤(DLBCL)患者血清蛋白质质谱,用生物化学法测定T—NHL患者血清乳酸脱氢酶(LDH)水平,用酶联免疫吸附法(ELISA)测定β2-微球蛋白(β2-MG)水平。分析T—NHL患者与DLBCL患者间质谱检测差异表达的蛋白质,同时分析差异蛋白质丰度与疾病分期、LDH及β2-MG水平的相关性。结果与DLBCL患者比较,在T—NHL患者血清中共检测出9个差异蛋白质,其相对分子质量分别为1142.67、1451.43、1472.49、1512.03、3194.22、3267.41、3933.86、4593.12、9182.24。这些差异蛋白质的表达水平在T—NHL不同分期间差异无统计学意义(均P〉0.05)。4593.12和9182.24蛋白质质谱在T—NHL中高表达,在这两种蛋白质阳性组中,LDH表达水平分别为(290.82±29.95)u/L、(283.94±100.94)U/L,明显高于阴性组的(169.22±55.42)u/L、(169.50±59.25)U/L(t=-3.199,P=0.004;t=-2.378,P=0.026),两组蛋白质的峰值与LDH的水平呈正相关(r=0.265,r=0.178,均P〈0.01);在这两种蛋白质阳性组与阴性组间β2-MG表达水平差异无统计学意义(P〉0.05)。其他7种蛋白质在T—NHL患者血清中低表达,LDH、β2-MG水平在这些蛋白质质谱中差异无统计学意义(均P〉0.05)。结论相对分子质量为4593.12和9182.24的蛋白质可能是鉴别T-NHL的特异血清学标志,它们可和LDH联合用于评估患者的肿瘤负荷,为临床治疗提供一定的指导。
Objective To find differential expression proteins in patients with T cell non-Hodgkin's lymphoma (T-NHL) by using surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technique and study their related clinical application value and prospect. Methods Serum protein of 36 T-NHL patients and 30 DLBCL patients were detected by the SELDI-TOF-MS technique and weak cation exchange (wcx-2) chip. Lactate dehydrogenase (LDH) was detected by biochemistry method. Beta- 2-microglobulin (β2-MG) was detected by enzyme-linked immunesorbent assay (ELISA). The significant different protein spectrometry were analyzed between DLBCL patients and T-NHL patients. The correlation analysis with protein spectrometry, disease staging, LDH and β2-MG were analyzed with Spearman. Results Nine potential candidate proteins, including the peak intensity of M/Z 1142.67, 1451.43, 1472.49, 1512.03, 3194.22, 3267.41, 3933.86, 4593.12 and 9182.24, were identified in T-NHL patients. The 9 protein markers had no contact with disease staging of T-NHL (P 〉 0.05). The protein markers of 4593.12 and 9182.24 were high level in T-NHL patients. LDH in these two protein markers' positive group [(290.82±29.95) U/L, (283.94±100.94) U/L] was higher than that in negative group [(169.22±55.42) U/L, (169.50±59.25) U/L] (t = -3.199, P = 0.004; t = -2.378, P = 0.026), and LDH was positive correlation with these two protein spectrometry (r = 0.265, r = 0.178, P 〈 0.01). There was no statistically significant difference of β2-MG between these two protein markers' positive group and negative group (P 〉 0.05). The other 7 protein markers were low level in T-NHL patients, and there was no statistically significant difference of LDH and β2-MG in these 7 protein markers (P 〉 0.05). Conclusion The protein marker of 4593.12 and 9182.24 may be the specific serological markers to identify T-NHL. The combination of these two protein markers and LDH may assess the tumor load, and provide guiding value for clinical treatment.
出处
《白血病.淋巴瘤》
CAS
2012年第8期468-471,共4页
Journal of Leukemia & Lymphoma
基金
基金项目:国家863计划(2006AA02090406)
山西省自然科学基金(981073)
关键词
光谱法
质量
基质辅助激光解吸电离
T淋巴细胞
淋巴瘤
非霍奇金
Spectrometry, mass, matrix-assisted laser desorption-ionization
T-lymphocytes
Lymphoma, non-Hodgkin's